Data from Apalutamide + Abiraterone Acetate plus Prednisone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation in Very High-Risk Prostate Cancer: A Single-Arm, Phase 2 Study
2026-06-17
Supplementary Table S1 from Apalutamide + Abiraterone Acetate plus Prednisone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation in Very High-Risk Prostate Cancer: A Single-Arm, Phase 2 Study
2026-06-17
IP44-13 DISEASE PRESENTATION AND ONCOLOGIC OUTCOMES OF EARLY-ONSET PROSTATE CANCER IN A CONTEMPORARY COHORT
The Journal of Urology · 2026-04-27
PD23-15 SAFETY OF RUCAPARIB VS DOCETAXEL OR SECOND-GENERATION ANDROGEN RECEPTOR PATHWAY INHIBITOR THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND A <i>BRCA</i> MUTATION IN TRITON3
The Journal of Urology · 2026-04-27
Abstract 1024: CIN signatures as biomarkers of drug sensitivity: Real-world evidence from DNA targeted sequencing data
Cancer Research · 2026-04-03
Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer
JCO Precision Oncology · 2026-03-01
Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02).
Journal of Clinical Oncology · 2026-03-01
Phase 1, dose-escalation study of KTX-2001 (an NSD2 inhibitor) alone and in combination with darolutamide for metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology · 2026-03-01
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
Journal of Clinical Oncology · 2026-02-26 · 12 citations
Apalutamide + Abiraterone Acetate plus Prednisone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation in Very High-Risk Prostate Cancer: A Single-Arm, Phase 2 Study
Clinical Cancer Research · 2026-02-19
DH1 and IDH2 Mutations in prostate cancer
European Urology Open Science · 2025-11-01
BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function
Proceedings of the National Academy of Sciences · 2025-06-03 · 8 citations
Investigation of clonal hematopoiesis frequency following PARP inhibitor treatment and its association with prior platinum therapy exposure.
Journal of Clinical Oncology · 2025-05-28 · 1 citations
Abstract CT003: Non operative management of mismatch repair deficient tumors
Cancer Research · 2025-05-22
Nonoperative Management of Mismatch Repair–Deficient Tumors
New England Journal of Medicine · 2025-04-27 · 160 citations
Abstract CT192: Orally administered MOMA-313 as monotherapy or combination therapy in participants with advanced or metastatic solid homologous recombination (HR)-deficient tumors: Phase 1 study design
Cancer Research · 2025-04-25
BRCA2 reversion mutation-independent resistance to PARP inhibition in prostate cancer through loss of function perturbations in the DNA pre-replication complexPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-04-24 · 1 citations
Abstract 6627: Clonal architecture analysis of response to PARP inhibition in prostate cancer
Cancer Research · 2025-04-21
MP16-07 RUCAPARIB VS DOCETAXEL OR SECOND-GENERATION ANDROGEN RECEPTOR PATHWAY INHIBITOR THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH <i>BRCA</i> MUTATIONS WITH OR WITHOUT LIVER METASTASES IN TRITON3
The Journal of Urology · 2025-04-08 · 1 citations
State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer
American Society of Clinical Oncology Educational Book · 2025-03-20 · 8 citations